Steadier journeys.
Better clinical decisions.
Assess motion-linked symptoms, identify when to investigate, and plan prevention with an India-focused medicine reference.
Start with the pattern
Test the clinical concern
Typical episodes: no routine tests
A recurrent pattern of nausea, pallor or sweating during travel, resolving after exposure, is usually assessed clinically. Do not order routine CT, MRI or vestibular testing for this pattern alone.
Examine first
Check vitals and hydration; consider orthostatic BP. Examine gait, eye movements, neurological signs and hearing when symptoms are atypical. Review migraine, medicines and pregnancy possibility.
HINTS is for trained clinicians evaluating the appropriate acute vestibular syndrome; it is not a self-test or a general motion sickness screen.
Selective tests
- Repeated vomiting / dehydration: electrolytes, renal function and glucose as indicated.
- Pregnancy test when clinically relevant, with consent.
- Palpitations, syncope or QT-risk medicines: ECG as indicated.
- Hearing changes: audiometry / ENT review.
- Suspected central disease: urgent stroke / neurology pathway; imaging chosen by the evaluating team.
Differential guide
| Pattern | Consider | Next step |
|---|---|---|
| Brief spinning on turning in bed | BPPV | Appropriate positional examination |
| Recurrent dizziness with migraine features | Vestibular migraine | Clinical migraine assessment |
| Continuous new vertigo / gait impairment | Peripheral or central vestibular disease | Urgent assessment if severe or new |
| Persistent rocking after a voyage | Mal de débarquement syndrome | Vestibular specialist review if persistent |
Prevention comes first
Before the journey
Sleep adequately, avoid alcohol and choose a seat with less movement: near aircraft wings or the middle of a ship. Keep the head supported; look towards a stable distant view. Avoid reading and screens.
During symptoms
Reduce or stop the provoking activity safely, get fresh air, rest and use small frequent sips of fluid / ORS. Ongoing vomiting may prevent oral absorption; clinician-directed treatment and hydration may be needed.
Ginger has uncertain benefit; acupressure bands have not reliably outperformed placebo.
Medication reference
| Agent | Adult reference / timing | Key precautions |
|---|---|---|
| Meclizine | 25–50 mg orally before exposure; allow around 2 hours for onset. Repeat only according to the specific local label. | Sedation, dry mouth; review anticholinergic risks. |
| Dimenhydrinate | 50–100 mg orally; allow around 2 hours for onset. Follow product-specific repeat interval and daily maximum. | Sedation and additive effects with other antihistamines. |
| Promethazine | 25 mg orally may be considered by a clinician for intense exposure; onset about 2 hours. Follow local label. | Marked sedation; contraindicated below 2 years. No injection self-use. |
| Cinnarizine | NHS 15 mg formulation: 30 mg 2 hours before travel, then 15 mg every 8 hours if needed. | Indian 25/75 mg products are not tablet-for-tablet equivalents of this regimen. Check local product instructions. Review Parkinsonism. |
| Scopolamine / hyoscine hydrobromide | Adult patch delivering 1 mg over 72 hours; allow 6–8 hours before exposure. Follow the exact product label. | Do not cut or double patches. Avoid in children, glaucoma or urinary retention; review heat-related adverse effects. Indian supply not verified. |
Spinfree & similar combinations
Spinfree contains cinnarizine 20 mg + dimenhydrinate 40 mg. The Indian prescribing information indicates treatment of vertigo, so this app does not automatically recommend it for uncomplicated motion sickness.
For clinician reference, its vertigo label uses one tablet three times daily after food for no more than four weeks. Avoid in severe renal impairment (CrCl <25 mL/min), severe hepatic disease, angle-closure glaucoma or urinary retention. Pregnancy safety is not established; avoid during breastfeeding. Not a pediatric travel regimen. Check the full label and interactions.
Read Spinfree prescribing information ↗Medicines that do not replace vestibular prevention
Ondansetron and newer non-sedating antihistamines are ineffective for motion sickness. Betahistine and pregnancy nausea combinations are not default travel-sickness treatments. Stimulants are not recommended to counteract sedation.
Special populations
Children, pregnant or breastfeeding patients, older adults and people with significant comorbidities need individualized review. The app deliberately generates no pediatric or pregnancy prescription.
Know the ingredient.
Then check the brand.
Five references per listed group, including Spinfree. Cinnarizine also has H1 activity; the groups below organize the directory rather than imply entirely separate mechanisms.
Antimuscarinic availability gap
Five Indian motion-sickness brands of scopolamine / hyoscine hydrobromide could not be verified. No invented brands are included. Hyoscine butylbromide (such as abdominal antispasmodic products) is not a substitute.
Prices and stock change; use each linked listing for the current pack price. Retail listing evidence is separate from clinical treatment evidence.
Close the loop
After an episode
- Confirm improvement once the provoking motion ends.
- Check hydration, intake and urine output after vomiting.
- Review sedation, blurred vision, confusion, urinary difficulty or abnormal movements.
- Arrange review for persistent symptoms, new susceptibility or recurrence without travel.
Before the next journey
- Record trigger, duration and functional impact.
- Review which positioning measures helped.
- Check medicine, dose, timing and adverse effects with the clinician.
- Discuss a supervised suitability check / trial before travel where appropriate; do not drive during a trial.
- Consider vestibular / migraine evaluation for atypical recurrent episodes.
Escalate immediately
New neurological symptoms, collapse, severe headache, inability to walk, blood in vomit or severe dehydration need urgent assessment. Sudden hearing loss also needs prompt care.
Sources you can inspect
Clinical content is an original summary based on the supplied PDF, current public guidance and product labels. The PDF itself is not included in the public source package.
Scope & privacy
This is a rule-based clinician reference, not a validated diagnostic device or prescribing system. Assessment input stays in the current page memory, is cleared on reset / reload, and is never uploaded. There is no login, analytics or patient database. External reference links open third-party websites.
Evidence check: 1 November 2026. Clinical decisions and product availability must be rechecked at the point of care.